IntelGenx Technologies (IGXT) S-1/A 4 Dec 13 2013 FY IPO registration (amended) Financial data

Document_and_Entity_Informatio

Document and Entity Information	21 Months Ended
	Sep. 30, 2013
Document Type	'S-1
Amendment Flag	'true
Amendment Description	'
Document Period End Date	30-Sep-13
Trading Symbol	'igxt
Entity Registrant Name	'IntelGenx Technologies Corp.
Entity Central Index Key	'0001098880
Current Fiscal Year End Date	'--12-31
Entity Filer Category	'Smaller Reporting Company
Entity Current Reporting Status	'Yes
Entity Voluntary Filers	'No
Entity Well Known Seasoned Issuer	'No
Document Fiscal Year Focus	'2013
Document Fiscal Period Focus	'FY

Consolidated_Balance_Sheets

Consolidated Balance Sheets (USD $)	Sep. 30, 2013	Dec. 31, 2012	Dec. 31, 2011
In Thousands, unless otherwise specified
Current	'	'	'
Cash and cash equivalents	$2,551	$2,059	$3,505
Accounts receivable	55	1,282	263
Prepaid expenses	222	102	68
Loan receivable	'	0	85
Investment tax credits receivable	212	213	375
Total Current Assets	3,040	3,656	4,296
Leasehold Improvements and Equipment, net	608	387	149
Intangible Assets	87	116	125
Total Assets	3,735	4,159	4,570
Current	'	'	'
Accounts payable and accrued liabilities	313	1,058	666
Deferred license revenue	308	308	0
Total Current Liabilities	621	1,366	666
Deferred License Revenue, non-current portion	386	615	0
Total Liabilities	1,007	1,981	666
Commitments	'	0	0
Shareholders' Equity	'	'	'
Capital Stock	1	0	0
Additional Paid-in-Capital	17,919	16,342	15,918
Accumulated Deficit	-15,458	-14,463	-12,213
Accumulated Other Comprehensive Income	266	299	199
Total Shareholders' Equity	2,728	2,178	3,904
Total Liabilities and Stockholders Equity	$3,735	$4,159	$4,570

Consolidated_Statement_of_Comp

Consolidated Statement of Comprehensive Income (Loss) (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, except Share data, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Revenues	'	'	'	'	'	'
Royalties	$28	$0	$119	$0	'	'
License and other revenue	72	0	685	120	'	'
Revenue	'	'	'	'	1,198	433
Other Income	'	'	'	'	10	7
Total Revenues	100	0	804	120	1,208	440
Expenses	'	'	'	'	'	'
Research and development expense	191	287	406	838	1,935	1,524
Research and development tax credits	'	'	'	'	-212	-188
Selling, general and administrative expense	491	404	1,341	1,175	'	'
Management salaries	'	'	'	'	716	586
General and administrative	'	'	'	'	347	333
Professional fees	'	'	'	'	582	594
Amortization of tangible assets	7	10	24	27	46	37
Amortization of intangible assets	10	0	29	0	'	'
Foreign exchange loss	'	'	'	'	-41	-3
Interest and financing fees	'	'	'	'	3	3
Total Costs and Expenses	699	701	1,800	2,040	3,458	2,892
Loss from Operations	-599	-701	-996	-1,920	'	'
Other Income	'	'	'	'	'	'
Interest and other income	0	3	1	8	'	'
Total Other Income	0	3	1	8	'	'
Loss Before Income Taxes	'	'	'	'	-2,250	-2,452
Income taxes	'	'	'	'	0	0
Net Loss	-599	-698	-995	-1,912	-2,250	-2,452
Other Comprehensive Income (Loss)	'	'	'	'	'	'
Foreign currency translation adjustment	73	109	-33	128	100	49
Comprehensive Loss	($526)	($589)	($1,028)	($1,784)	($2,150)	($2,403)
Basic and Diluted Weighted Average Number of Shares Outstanding	52,687,253	49,711,617	52,474,772	49,553,305	49,637,908	43,736,003
Basic and Diluted Loss Per Common Share	($0.01)	($0.01)	($0.02)	($0.04)	($0.04)	($0.05)

Consolidated_Statement_of_Cash

Consolidated Statement of Cash Flows (USD $)	3 Months Ended		9 Months Ended		12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012	Dec. 31, 2012	Dec. 31, 2011
Funds Provided (Used) - Operating Activities	'	'	'	'	'	'
Net profit (loss)	($599)	($698)	($995)	($1,912)	($2,250)	($2,452)
Amortization	17	10	53	27	46	37
Stock-based compensation	35	14	82	43	59	51
Accounts receivable write-off	'	'	'	'	0	53
Total adjustments	-547	-674	-860	-1,842	-2,145	-2,311
Changes in assets and liabilities	'	'	'	'	'	'
Accounts receivable	305	245	1,227	118	-1,019	-38
Prepaid and other assets	-128	16	-120	1	-34	-21
Other receivables	56	-34	1	195	247	-263
Accounts payable and other accrued liabilities	-23	-33	-745	-416	390	317
Deferred revenue	-74	0	-228	1,000	923	0
Net change in assets and liabilities	136	194	135	898	507	-5
Net cash provided (used) by operating activities	-411	-480	-725	-944	-1,638	-2,316
Financing Activities	'	'	'	'	'	'
Issuance of common stock and warrants	'	'	'	'	0	3,231
Proceeds from exercise of warrants and stock options	714	103	1,496	337	365	1,918
Transaction Costs	'	'	'	'	0	-369
Net cash provided by financing activities	714	103	1,496	337	365	4,780
Investing Activities	'	'	'	'	'	'
Additions to property and equipment	-99	-6	-260	-248	-270	-34
Additions to intangible assets	'	'	'	'	0	125
Net cash used in investing activities	-99	-6	-260	-248	-270	-159
Increase (Decrease) in Cash and Cash Equivalents	204	-383	511	-855	-1,543	2,305
Effect of Foreign Exchange on Cash and Cash Equivalents	63	96	-19	118	97	56
Cash and Cash Equivalents	'	'	'	'	'	'
Beginning of Period	2,284	3,055	2,059	3,505	3,505	1,144
End of Period	$2,551	$2,768	$2,551	$2,768	$2,059	$3,505

Consolidated_Statement_of_Shar

Consolidated Statement of Shareholders Equity (USD $)	Capital Stock [Member]	Additional Paid-In Capital [Member]	Accumulated Deficit [Member]	Accumulated Other Comprehensive Income [Member]	Total
In Thousands, except Share data
Beginning Balance at Dec. 31, 2010	$0	$11,087	($9,761)	$150	$1,476
Beginning Balance (Shares) at Dec. 31, 2010	39,581,271	'	'	'	'
Foreign currency translation adjustment	'	'	'	49	49
Issue of common stock, net of transaction costs of $390	'	2,024	'	'	2,024
Issue of common stock, net of transaction costs of $390 (Shares)	4,821,342	'	'	'	'
Warrants issued, net of transaction costs of $132	'	685	'	'	685
Agents' Warrants	'	153	'	'	153
Warrants exercised	'	1,458	'	'	1,458
Warrants exercised (Shares)	3,418,009	'	'	'	'
Agents warrants exercised	'	142	'	'	142
Agents warrants exercised (Shares)	299,406	'	'	'	'
Options exercised	'	318	'	'	318
Options exercised (Shares)	775,000	'	'	'	'
Stock-based compensation	'	51	'	'	51
Net loss for the period	'	'	-2,452	'	-2,452
Ending Balance at Dec. 31, 2011	0	15,918	-12,213	199	3,904
Ending Balance (Shares) at Dec. 31, 2011	48,895,028	'	'	'	'
Foreign currency translation adjustment	'	'	'	100	100
Warrants exercised	'	233	'	'	233
Warrants exercised (Shares)	726,080	'	'	'	'
Agents warrants exercised	'	104	'	'	104
Agents warrants exercised (Shares)	219,313	'	'	'	'
Options exercised	'	28	'	'	28
Options exercised (Shares)	50,000	'	'	'	'
Stock-based compensation	'	59	'	'	59
Net loss for the period	'	'	-2,250	'	-2,250
Ending Balance at Dec. 31, 2012	0	16,342	-14,463	299	2,178
Ending Balance (Shares) at Dec. 31, 2012	49,890,421	'	'	'	'
Foreign currency translation adjustment	'	'	'	-33	-33
Warrants exercised	1	1,464	'	'	1,465
Warrants exercised (Shares)	3,098,500	'	'	'	'
Options exercised	'	31	'	'	31
Options exercised (Shares)	75,000	'	'	'	'
Stock-based compensation	'	82	'	'	82
Net loss for the period	'	'	-995	'	-995
Ending Balance at Sep. 30, 2013	$1	$17,919	($15,458)	$266	$2,728
Ending Balance (Shares) at Sep. 30, 2013	53,063,921	'	'	'	'

Basis_of_Presentation

Basis of Presentation	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Basis of Presentation [Text Block]	'		'
	1	Basis of Presentation	1.	Basis of Presentation
		The accompanying unaudited consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete consolidated financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. All such adjustments are of a normal and recurring nature.		IntelGenx Technologies Corp. (“IntelGenx” or the “Company”) prepares its financial statements in accordance with accounting principles generally accepted in the United States of America (“USA”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.
		These financial statements should be read in conjunction with the audited consolidated financial statements at December 31, 2012. Operating results for the three and nine months ended September 30, 2013 are not necessarily indicative of the results that may be expected for the year ending December 31, 2013. The Company prepares its financial statements in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). This basis of accounting involves the application of accrual accounting and consequently, revenues and gains are recognized when earned, and expenses and losses are recognized when incurred.		The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.
		The consolidated financial statements include the accounts of the Company and its subsidiary companies. On consolidation, all inter-entity transactions and balances have been eliminated.		The financial statements are expressed in U.S. funds.
		The financial statements are expressed in U.S. funds.
		Management has performed an evaluation of the Company’s activities through the date and time these financial statements were issued and concluded that there are no additional significant events requiring recognition or disclosure.

Nature_of_Business

Nature of Business	12 Months Ended
	Dec. 31, 2012
Nature of Business [Text Block]	'
	2.	Nature of Business
		The Company specializes in the development of pharmaceutical products in co-operation with various pharmaceutical companies.
		Technologies
		The Company has developed three proprietary delivery platforms; including an immediate release oral film “ VersaFilm™ ”, a mucoadhesive tablet “ AdVersa™ ” and a multilayer controlled release tablet “ VersaTab™ ”.
		The three technology platforms have been designed to address the challenges commonly encountered in oral drug delivery, such as first-pass metabolism, gastrointestinal (“GI”) side effects, or incomplete absorption of the drug in the GI tract. IntelGenx’ technologies are broadly applicable and have the ability to improve the performance of a wide variety of existing pharmaceutical compounds.
		Product Pipeline
		IntelGenx’ product pipeline currently consists of 9 products in various stages of development, including products for the treatment of hypertension, erectile dysfunction, benign prostatic hyperplasia, migraine, insomnia, idiopathic pulmonary fibrosis, allergies and pain management. Of the products currently under development, 6 utilize the VersaFilm™ technology, 2 utilize the VersaTab™ technology, and one utilizes the AdVersa™ technology.
		Approved and Commercialized Products
		The Company’s first FDA-approved product, Forfivo XL™, was launched in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP. Forfivo XL™ is indicated for the treatment of Major Depressive Disorder (MDD) and is the only extended-release bupropion HCl product to provide a once-daily, 450mg dose in a single tablet. The active ingredient in Forfivo XL is bupropion, the same active ingredient used in Wellbutrin XL®.
		Sales of the Company’s first commercialized product, a pre-natal multivitamin supplement, marketed in the USA as Gesticare®, were discontinued in the third quarter of 2011. The Company received final royalties from the sale of the product in the fourth quarter of 2011 from Azur Pharma, now part of Jazz Pharmaceuticals plc.

Adoption_of_New_Accounting_Sta

Adoption of New Accounting Standards	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Adoption of New Accounting Standards [Text Block]	'		'
	2	Adoption of New Accounting Standards	3.	Adoption of New Accounting Standards
		Revenue Recognition and Disclosures		In May 2011, the FASB issued Update No. 2011-04, “Fair Value Measurement (Topic 820): Amendments to Achieve Common Fair Value Measurement and Disclosure Requirements in U.S. GAAP and IFRSs”. The amendments in this Update result in common fair value measurement and disclosure requirements in U.S. GAAP and IFRSs. Consequently, the amendments change the wording used to describe many of the requirements in U.S. GAAP for measuring fair value and for disclosing information about fair value measurements. For many of the requirements, FASB does not intend for the amendments in this Update to result in a change in the application of the requirements in Topic 820. Some of the amendments clarify FASB’s intent about the application of existing fair value measurement requirements. Other amendments change a particular principle or requirement for measuring fair value or for disclosing information about fair value measurements. For public entities, ASU 2011-4 is effective during interim and annual periods beginning after December 15, 2011. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.
		In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about derivatives, repurchase agreements and reverse purchase agreements, and securities borrowing and securities lending transactions that are either offset in accordance with specific criteria or subject to a master netting arrangement or similar agreement. In January 2013, the FASB also issued Update No. 2013-01, which clarifies that ordinary trade receivables and receivables are not in the scope of ASU 2011-11. ASU 2011-11and ASU 2013-01are effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.		In June 2011, the FASB issued Update No. 2011-05, “Comprehensive Income (Topic 220): Presentation of Comprehensive Income”. Under the amendments, an entity has the option to present the total of comprehensive income, the components of net income, and the components of other comprehensive income either in a single continuous statement of comprehensive income or in two separate but consecutive statements. In both choices, an entity is required to present each component of net income along with total net income, each component of other comprehensive income along with a total for other comprehensive income, and a total amount for comprehensive income. This Update eliminates the option to present the components of other comprehensive income as part of the statement of changes in stockholders' equity. The amendments in this Update do not change the items that must be reported in other comprehensive income or when an item of other comprehensive income must be reclassified to net income. ASU 2011-05 should be applied retrospectively. For public entities, the amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2011. Early adoption is permitted. In December 2011 however, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.
		In February 2013, the FASB has issued Update No. 2013-02, “Comprehensive Income (Topic 220): Reporting of Amounts Reclassified Out of Accumulated Other Comprehensive Income”. This Update has been issued to improve the transparency of reporting these reclassifications. The amendments in this Update supersede and replace the presentation requirements for reclassifications out of accumulated other comprehensive income in ASUs 2011 - 05 and 2011 - 12 for all public and private organizations. The amendments would require an entity to provide additional information about reclassifications out of accumulated other comprehensive income. Public companies are required to comply with these amendments for all reporting periods (interim and annual), effective for reporting periods beginning after December 15, 2012. The adoption of this Statement did not have a material effect on the Company’s financial position or results of operations.

Significant_Accounting_Policie

Significant Accounting Policies	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Significant Accounting Policies [Text Block]	'		'
	3	Significant Accounting Policies	4.	Summary of Significant Accounting Policies
		Recently Issued Accounting Pronouncements		Revenue Recognition
		In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.		The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.
				IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.
		In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810 - 10, Consolidation—Overall, or Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.		In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows:
				$200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and
		In April 2013, the FASB issued Update No. 2013-07, “Presentation of Financial Statements – Liquidation Basis of Accounting”. The objective of this Update is to clarify when an entity should apply the liquidation basis of accounting and to provide principles for the measurement of assets and liabilities under the liquidation basis of accounting, as well as any required disclosures. These amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entities should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.		$500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product.
		In July 2013, the FASB issued Update No. 2013-11, “Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. The amendments in this ASU provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Early adoption and retrospective application is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.		Product Sales:
				The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013.
				Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.
				Use of Estimates
				The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.
				Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.
				Financial Instruments
				The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value.
				Cash and Cash Equivalents
				Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.
				Accounts Receivable
				The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.
				Investment Tax Credits
				Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.
				Leasehold Improvements and Equipment
				Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:
				On the declining balance method -
				Laboratory and office equipment	20%
				Computer equipment	30%
				On the straight-line method -
				Leasehold improvements	over the lease term
				Manufacturing equipment	5 – 10 years
			Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
			Intangible Assets
			Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
			Impairment of Long-lived Assets
			Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.
				Foreign Currency Translation
				The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:
			Assets and liabilities - at exchange rates in effect at the balance sheet date;
			Revenue and expenses - at average exchange rates prevailing during the year;
			Equity - at historical rates.
			Gains and losses arising from foreign currency translation are included in other comprehensive income.
			Income Taxes
			The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
			Unrecognized Tax Benefits
			The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
			Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.
				Share-Based Payments
				The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.
				The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.
				Loss Per Share
				Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.
				Fair Value Measurements
				ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
				Level 1:	Quoted market prices in active markets for identical assets or liabilities.
				Level 2:	Observable market based inputs or unobservable inputs that are corroborated by market data.
				Level 3:	Unobservable inputs that are not corroborated by market data.
			In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2012.
			Fair Value of Financial Instruments
			The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.
			Recent Accounting Pronouncements
			In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.
				In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements.

Leasehold_Improvements_and_Equ

Leasehold Improvements and Equipment	12 Months Ended
	Dec. 31, 2012
Leasehold Improvements and Equipment [Text Block]	'
	5.	Leasehold Improvements and Equipment
								2012		2011
		In US$ thousands				Accumulated		Net Carrying		Net Carrying
				Cost		Depreciation		Amount		Amount
		Manufacturing equipment	$	225	$	0	$	225	$	0
		Laboratory and office equipment		418		265		153		138
		Computer equipment		43		34		9		11
		Leasehold improvements		63		63		0		0
			$	749	$	362	$	387	$	149
		As of December 31, 2012 no depreciation has been recorded on manufacturing equipment as the equipment is not yet being utilized.

Intangible_Assets

Intangible Assets	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Intangible Assets [Text Block]	'		'
	4	Intangible Assets	6.	Intangible Assets
		As of September 30, 2013 NDA acquisition costs of $87 thousand (December 31, 2012 - $116 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL®. The asset is being amortized over its estimated useful life of 39 months. The Company commenced amortization upon commercial launch of the product in October 2012.		As of December 31, 2012 NDA acquisition costs of $116 thousand (December 31, 2011 - $125 thousand) were recorded as intangible assets on the Company’s balance sheet and represent the net book value of the final progress payment related to the acquisition of 100% ownership of Forfivo XL™. The asset will be amortized over its estimated useful life of 39 months and the Company commenced amortization upon commercial launch of the product in October 2012.

Deferred_License_Revenue

Deferred License Revenue	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Deferred License Revenue [Text Block]	'		'
	5	Deferred License Revenue	7.	Deferred License Revenue
		Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.		Deferred license revenue represents upfront payments received for the granting of licenses to the Company’s patents, intellectual property, and proprietary technology, for commercialization. Deferred license revenue is recognized in income over the period where sales of the licensed products will occur.
		Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue is being amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL® are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $694 thousand at September 30, 2013 that has not been recognized as revenue.		Upon entering into the licensing agreement with Edgemont Pharmaceuticals the Company received an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over a period of 39 months, which is the minimum period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.

Commitments

Commitments	12 Months Ended
	Dec. 31, 2012
Commitments [Text Block]	'
	8.	Commitments
		The Company currently operates out of a 3,500 square feet leasehold facility consisting of laboratories and office space at 6425 Abrams, Saint-Laurent, Quebec. The original lease agreement expired in August 2009, since when it has been extended for varying periods whilst the Company sought alternative premises. The most recent extension is defined as the day immediately preceding the fulfillment of certain conditions relating to the occupation of new leased premises at 6410-6420 Abrams. In the first half of 2013, the Company plans to enter into an addendum to its existing lease to include the relocation of the Company’s operations to larger premises consisting of approximately 28,600 of rentable square feet. The term of the amended lease is 10 years following relocation, which is expected to commence in the autumn of 2013 upon completion of certain leasehold improvements.
		As of December 31, 2012 future minimum payments under operating leases for facilities were as follows (in thousands):
	2013		15
	2014		0
	Total	$	15
	On October 1, 2009, the Company signed new agreements with each of Little Gem Life Science Partners and SectorSpeak Inc. for investor relation services in the USA and in Canada, respectively. Under the terms of these agreements, the Company was required to pay $4.5 thousand a month to Little Gem Life Science Partners and CDN$5.0 thousand (US$5.0 thousand) monthly to Sector Speak Inc. The Company renegotiated these agreements in May 2012 and reduced payments to $2.5 thousand and CDN$2.5 thousand (US$2.5 thousand) respectively. The agreements automatically renew unless specifically terminated.
	On May 7, 2010, the Company executed a Project Transfer Agreement with one of its former development partners whereby the Company acquired full rights to, and ownership of, Forfivo XL™, a novel, high strength formulation of Bupropion hydrochloride, the active ingredient in Wellbutrin XL®. In accordance with the Project Transfer Agreement, and following commercial launch of Forfivo XL™ in October 2012, the Company is required to pay to its former development partner 10% of net sales royalties received under the commercialization agreement that was executed with Edgemont Pharmaceuticals in February 2012.

Capital_Stock

Capital Stock

9 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Capital Stock [Text Block]

'

'

6

Capital Stock

9.

Capital Stock

September 30,

December 31,

2012

2011

2013

2012

Authorized -

Authorized -

100,000,000 common shares of $0.00001 par value

100,000,000 common shares of $0.00001 par value

20,000,000 preferred shares of $0.00001 par value

20,000,000 preferred shares of $0.00001 par value

Issued -

Issued -

49,890,421 (December 31, 2011 - 48,895,028) common shares

$

499

$

489

53,063,921 (December 31, 2012 - 49,890,421) common shares

$

531

$

499

On June 21, 2011, as part of two concurrent private placement offerings, the Company issued approximately 4.8 million shares of common stock, and three-year warrants to purchase up to approximately 2.4 million shares of common stock, for aggregate gross proceeds of approximately US$3.2 million. Each warrant entitles the holder to purchase one half of one common share at an exercise price of $0.74 per common share and expires 36 months after the date of issuance. Proceeds were allocated between the common shares and the warrants based on their relative fair value. The common shares were recorded at a value of $2,024 thousand. (See note 10 for the portion allocated to the warrants).

The private placements consisted of a definitive securities purchase agreement with certain accredited and institutional investors for the issuance and sale in a private placement transaction (the "US Private Offering") of 2,582,536 shares and warrants to purchase up to 1,291,268 shares of common stock, for aggregate gross proceeds of approximately $1.7 million, and a definitive subscription agreement solely with Canadian investors for the issuance and sale in a concurrent non-brokered private placement transaction (the "Canadian Private Offering") of 2,238,806 shares and warrants to purchase up to 1,119,403 shares of common stock, for aggregate gross proceeds of approximately $1.5 million.

The Company paid an agent cash commissions in the amount of approximately $121 thousand, representing 7% of the aggregate gross proceeds received by the Company in the US Private Offering, plus expenses in the amount of approximately $28 thousand, and issued warrants to the agent to purchase 180,778 shares of common stock, representing 7% of the amount of shares sold in the US Private Offering. The Company also paid cash finder's fees in the amount of approximately $105 thousand, representing 7% of the aggregate gross proceeds received by the Company in the Canadian Private Offering; and issued warrants to purchase 156,716 shares of common stock, representing 7% of the amount of shares sold in the Canadian Private Offering. Each warrant entitles the holder to purchase one half of one common share at an exercise price of $0.74 per common share and expires 36 months after the date of issuance.

In addition, the Company paid approximately $114 thousand in cash consideration for other transaction costs, which have been reflected as a reduction of the common shares and the warrants based on their relative fair values. All of the above transaction costs have been reflected as a reduction to the common shares and the warrants based on their relative fair values.

In the year ended December 31, 2012 a total of 50,000 (2011 – 775,000) stock options were exercised for 50,000 (2011 – 775,000) common shares having a par value of $0 thousand (2011 - $Nil) in aggregate, for cash consideration of $28 thousand ($318 thousand), resulting in an increase in additional paid-in capital of $28 thousand (2011 – $318 thousand).

During the year ended December 31, 2012 a total of 219,313 (2011 - 299,406) agents’ warrants were exercised for 219,313 (2011 - 299,406) common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand (2011 - $142 thousand), resulting in an increase in additional paid- in capital of approximately $104 thousand (2011 - $142 thousand).

Also in the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

In the year ended December 31, 2011 a total of 4,366,904 warrants were exercised, of which 2,902,618 warrants were exercised for 2,902,618 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $1,458 thousand, resulting in an increase in additional paid-in capital of approximately $1,458 thousand, and a total of 1,464,286 warrants were exercised for 515,391 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.

Additional_PaidIn_Capital

Additional Paid-In Capital	9 Months Ended			12 Months Ended
	Sep. 30, 2013			Dec. 31, 2012
Additional Paid-In Capital [Text Block]	'			'
	7	Additional Paid-In Capital		10.	Additional Paid-In Capital
		Stock options			Stock Options
		On April 24, 2013 the Company granted 480,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.65 per share and vest on December 31, 2015. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $157 thousand, using the following assumptions:			In November 2006, the Company adopted the 2006 Stock Incentive Plan ("Plan") for the purpose of issuing both Incentive Options and Nonqualified Options to officers, employees, directors and eligible consultants of the Company. A total of 1,600,749 shares of common stock were reserved for issuance under this plan. Options may be granted under the Plan on terms and at prices as determined by the Board of Directors except that the options cannot be granted at less than 100%, of the fair market value of the common stock on the date of the grant. Each option will be exercisable after the period or periods specified in the option agreement, but no option may be exercised after the expiration of 10 years from the date of grant. All options granted to individuals other than non- employee directors will have a total vesting period of 24 months from the date of grant, with one quarter of the total options granted vesting and becoming exercisable every six months. Options granted to non-employees may vest and become 100% fully exercisable immediately upon grant.
		Expected volatility	78%		At the Annual General Meeting on September 8, 2008 the shareholders of the Company approved to amend the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 1,600,749 to 2,074,000, or 10% of the Company’s issued and outstanding common shares as of July 28, 2008.
		Expected life	3.83 years		A modification was made to the 2006 Stock Option Plan. The life of the options was reduced from 10 years to 5 years to comply with the regulations of the Toronto Stock Exchange. Accordingly, because the grant-date fair value of the modified options was less than the fair value of the original options measured immediately before the modification, no incremental share-based compensation expense resulted from the modification.
		Risk-free interest rate	0.34%
		Dividend yield	nil		At the Annual General Meeting on June 3, 2010, the Shareholders of the Company approved an amendment to the 2006 Stock Option Plan to increase the number of shares available for issuance under the Plan from 2,074,000 to 3,308,127, or 10% of the Company’s issued and outstanding shares as of April 5, 2010.
	On April 24, 2013 the Company granted 200,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.65 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $59 thousand, using the following assumptions:			On May 12, 2011 the Company granted 50,000 stock options to an employee to purchase common shares. The stock options are exercisable at $0.52 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $16 thousand, using the following assumptions:
		Expected volatility	77%		Expected volatility	115%
		Expected life	3.13 years		Expected life	3.1 years
		Risk-free interest rate	0.34%		Risk-free interest rate	0.96%
		Dividend yield	nil		Dividend yield	nil
	On August 6, 2013 the Company granted 35,000 stock options to a non-employee director to purchase common shares. The stock options are exercisable at $0.65 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions:			On November 29, 2011 the Company granted 115,000 stock options to two non-employee directors, 40,000 stock options to a director, 50,000 stock options to two officers, and 35,000 stock options to two employees, to purchase common shares. The stock options are exercisable at $0.54 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $74 thousand, using the following assumptions:
		Expected volatility	75%		Expected volatility	101%
		Expected life	3.13 years		Expected life	3.1 years
		Risk-free interest rate	0.62%		Risk-free interest rate	0.40%
		Dividend yield	nil		Dividend yield	nil
	During the nine month period ended September 30, 2013 a total of 75,000 (2012 - nil) stock options were exercised for 75,000 (2012 - nil) common shares having a par value of $0 thousand in aggregate, for cash consideration of $31 thousand (2012 - $Nil), resulting in an increase in additional paid-in capital of $31 thousand (2012 - $Nil).			On June 13, 2012 the Company granted 40,000 stock options to two employees to purchase common shares. The stock options are exercisable at $0.51 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions:
	Compensation expenses for stock-based compensation of $82 thousand and $43 thousand were recorded during the nine month period ended September 30, 2013 and 2012 respectively. Of the amount expensed in 2013, $67 thousand (2012 - $41 thousand) relates to stock options granted to employees and directors, and $15 thousand (2012 - $1 thousand) relates to options granted to independent third party consultants. In addition, $1 thousand was expensed in 2012 related to stock options granted to investor relations firms as compensation for investor relation services. As at September 30, 2013, the Company has $202 thousand (2012 - $63 thousand) of unrecognized stock-based compensation.				Expected volatility	83%
					Expected life	3.1 years
	Warrants				Risk-free interest rate	0.40%
					Dividend yield	nil
	During the nine month period ended September 30, 2013 a total of 3,098,500 (2012 - 1,424,981) warrants were exercised for 3,098,500 (2012 - 945,393) common shares having a par value of $0 thousand in aggregate, for cash consideration of $1,465 thousand (2012 - $337 thousand), resulting in an increase in additional paid-in capital of $1,464 thousand (2012 - $337 thousand).				On August 8, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.55 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $12 thousand, using the following assumptions:
					Expected volatility	81%
					Expected life	1.8 years
					Risk-free interest rate	0.38%
					Dividend yield	nil
				On December 4, 2012 the Company granted 30,000 stock options to an employee who is also a director and 25,000 stock options to an officer to purchase common shares. The stock options are exercisable at $0.60 per share and vest over 2 years at 25% every six months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $15 thousand, using the following assumptions:
					Expected volatility	78%
					Expected life	3.1 years
					Risk-free interest rate	0.34%
					Dividend yield	nil
				On December 12, 2012 the Company granted 50,000 stock options to a consultant to purchase common shares. The stock options are exercisable at $0.62 per share and vest over 1 year at 25% every three months. The stock options were accounted for at their fair value, as determined by the Black-Scholes valuation model, of approximately $10 thousand, using the following assumptions:
					Expected volatility	70%
					Expected life	1.8 years
					Risk-free interest rate	0.25%
					Dividend yield	nil
				During the year ended December 31, 2012 a total of 50,000 (2011 – 775,000) stock options were exercised for 50,000 (2011 – 775,000) common shares having a par value of $0 thousand (2011 - $Nil) in aggregate, for cash consideration of $28 thousand ($318 thousand), resulting in an increase in additional paid-in capital of $28 thousand (2011 – $318 thousand). The intrinsic value of the stock options exercised, as at the date of exercise, totaled $4 thousand.
					Information with respect to stock option activity for 2011 and 2012 is as follows:
										Weighted average
							Number of options			exercise price
										$
					Outstanding – January 1, 2011		1,698,088			0.53
					Granted		290,000			0.54
					Forfeited		(150,000	)		(0.76	)
					Expired		(65,000	)		(0.59	)
					Exercised		(775,000	)		(0.41	)
					Outstanding – December 31, 2011		998,088			0.59
					Granted		195,000			0.57
					Forfeited		(45,000	)		(0.49	)
					Expired		(32,500	)		(1.15	)
					Exercised		(50,000	)		(0.55	)
					Outstanding – December 31, 2012		1,065,588			0.58
					Details of stock options outstanding as at December 31, 2012 are as follows:
						Outstanding options								Exercisable options
												Weighted			Weighted
									Weighted average			average	Aggregate		average	Aggregate
				Exercise		Number of			remaining			exercise	intrinsic	Number of	exercise	intrinsic
				prices		options			contractual life			price	value	options	price	value
				$					(years)			$	$		$	$
				0.31		25,000			1.25			0.31		25,000	0.31
				0.37		75,000			2.67			0.37		75,000	0.37
				0.45-0.47		175,000			1.42			0.46		175,000	0.46
			0.51		40,000			4.5			0.51		0	0
			0.52-0.54		270,000			3.89			0.54		147,500	0.54
			0.55		50,000			2.67			0.55		12,500	0.55
			0.6		55,000			5			0.6		0	0
			0.61		125,000			1.51			0.61		125,000	0.61
			0.62		50,000			3			0.62		0	0
			0.85		200,588			0.63			0.85		200,588	0.85
					1,065,588			2.6			0.58	114,050	760,588	0.59	86,725
			Stock-based compensation expense recognized in 2012 in regards to the stock options was $59 thousand (2011 - $51 thousand). As of December 31, 2012, total unrecognized compensation expense related to unvested stock options was $72 thousand (2011 - $92 thousand), of which $17 thousand (2011 $Nil) relates to options granted to consultants. The amount of $72 thousand will be recognized as an expense over a period of two years. A change in control of the Company due to acquisition would cause the vesting of the stock options granted to employees and directors to accelerate and would result in $55 thousand being charged to stock based compensation expense.
			Warrants
			On June 21, 2011 the Company issued approximately 4.8 million stock purchase warrants exercisable into approximately 2.4 million common shares at $0.74 per share which expire on June 21, 2014. The stock purchase warrants were issued in connection with the June 21, 2011 private placements described in note 9. The stock purchase warrants were valued at $817 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below:
				Expected volatility	117%
				Expected life	3 years
				Risk-free interest rate	0.69%
				Dividend yield	nil
				On June 21, 2011 the Company issued approximately 0.3 million agents’ stock purchase warrants exercisable into approximately 0.3 million common shares at $0.74 per share which expire on June 21, 2014. The stock purchase warrants were issued in connection with the June 21, 2011 private placements described in note 9. The stock purchase warrants were valued at $153 thousand based on their relative fair value, as determined by the Black-Scholes valuation model using the assumptions below:
				Expected volatility	117%
				Expected life	3 years
				Risk-free interest rate	0.69%
				Dividend yield	nil
			During the year ended December 31, 2012 a total of 219,313 (2011 - 299,406) agents’ warrants were exercised for 219,313 (2011 - 299,406) common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $104 thousand (2011 - $142 thousand), resulting in an increase in additional paid-in capital of approximately $104 thousand (2011 - $142 thousand).
			Also in the year ended December 31, 2012 a total of 1,205,668 warrants were exercised, of which 491,382 warrants were exercised for 491,382 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $233 thousand, resulting in an increase in additional paid-in capital of approximately $233 thousand, and a total of 714,286 warrants were exercised for 234,698 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.
			In the year ended December 31, 2011 a total of 4,366,904 warrants were exercised, of which 2,902,618 warrants were exercised for 2,902,618 common shares having a par value of $0 thousand in aggregate, for cash consideration of approximately $1,458 thousand, resulting in an increase in additional paid-in capital of approximately $1,458 thousand, and a total of 1,464,286 warrants were exercised for 515,391 common shares in cashless exercises, resulting in an increase in additional paid-in capital of $Nil.
				Information with respect to warrant activity for 2011 and 2012 is as follows:
						Number of			Weighted average
						warrants			exercise price
						(All Exercisable)			$
				Outstanding – January 1, 2011		21,291,223			0.66
				Attached to private placements		2,748,165			0.74
				Agents’ warrants exercised		(299,406	)		(0.47	)
				Exercised		(4,366,904	)		(0.51	)
				Outstanding - December 31, 2011		19,373,078			0.71
				Agents’ warrants exercised		(219,313	)		(0.47	)
				Exercised		(1,205,668	)		(0.48	)
				Expired		(11,843,932	)		(0.80	)
				Outstanding - December 31, 2012		6,104,165			0.59

Income_Tax

Income Tax	12 Months Ended
	Dec. 31, 2012
Income Tax [Text Block]	'
	11.	Income Taxes
		Income taxes reported differ from the amount computed by applying the statutory rates to losses. The reasons are as follows:
				2012			2011
		Statutory income taxes	$	( 605	)	$	( 694	)
		Net operating losses for which no tax benefits have been recorded		368			514
		Excess of depreciation over capital cost allowance		3			(2	)
		Non-deductible expenses		18			4
		Undeducted research and development expenses		273			231
		Tax deductible portion of transaction costs		-			-
		Investment tax credit		(57	)		(53	)
		Modification of warrants terms		-			-
			$	-		$	-
	The major components of the deferred tax assets classified by the source of temporary differences are as follows:
				2012			2011
		Leasehold Improvements and equipment	$	13		$	14
		Net operating losses carryforward		2,278			2,140
		Undeducted research and development expenses		1,301			1,141
		Non-refundable tax credits carryforward		914			807
				4,506			4,102
		Valuation allowance		(4,506	)		(4,102	)
			$	-		$	-
	The valuation allowance at December 31, 2011 was $4,102 thousand. The net change in the valuation allowance during the period ended December 31, 2012, was an increase of $404 thousand. In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred income tax assets will not be realized. The ultimate realization of deferred income tax assets is dependent upon the generation of future taxable income during the periods in which those temporary differences become deductible. Management considers the scheduled reversal of deferred income tax liabilities, projected future taxable income, and tax planning strategies in making this assessment. Based on consideration of these items, management has determined that enough uncertainty exists relative to the realization of the deferred income tax asset balances to warrant the application of a full valuation allowance as of December 31, 2012.
		There were Canadian and provincial net operating losses of approximately $8,390 thousand (2011 - $7,608 thousand) and $8,566 thousand (2011 - $7,437 thousand) respectively, that may be applied against earnings of future years. Utilization of the net operating losses is subject to significant limitations imposed by the change in control provisions. Canadian and provincial losses will be expiring between 2027 and 2032. A portion of the net operating losses may expire before they can be utilized.
		As at December 31, 2012, the Company had non-refundable tax credits of $914 thousand (2011 - $803 thousand) of which $24 thousand is expiring in 2017, $213 thousand is expiring in 2018, $193 thousand is expiring in 2019, $186 thousand is expiring in 2020, $187 thousand is expiring in 2021 and $111 thousand is expiring in 2022 and undeducted research and development expenses of $4,464 thousand (2011 - $3,656 thousand) with no expiration date.
		The deferred tax benefit of these items was not recognized in the accounts as it has been fully provided for.
		Unrecognized Tax Benefits
		The Company does not expect its unrecognized tax benefits to change significantly over the next twelve months.
		Tax Years and Examination
		The Company files tax returns in each jurisdiction in which it is registered to do business. For each jurisdiction a statute of limitations period exists. After a statute of limitations period expires, the respective tax authorities may no longer assess additional income tax for the expired period. Similarly, the Company is no longer eligible to file claims for refund for any tax that it may have overpaid. The following table summarizes the Company’s major tax jurisdictions and the tax years that remain subject to examination by these jurisdictions as of December 31, 2012:
	Tax Jurisdictions		Tax Years
	Federal - Canada		2010 and onward
	Provincial - Quebec		2010 and onward

Statement_of_Cash_Flows_Inform

Statement of Cash Flows Information	12 Months Ended
	Dec. 31, 2012
Statement of Cash Flows Information [Text Block]	'
	12.	Statement of Cash Flows Information
		In US$ thousands		2012		2011
		Additional Cash Flow Information:
		Interest paid	$	3	$	3

Related_Party_Transactions

Related Party Transactions	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Related Party Transactions [Text Block]	'		'
	8	Related Party Transactions	13.	Related Party Transactions
		Included in management salaries for the nine months ended September 30, 2013 are $8 thousand (2012 - $5 thousand) for options granted to the Chief Executive Officer, $24 thousand (2012 - $Nil) for options granted to the Chief Operating Officer and $19 thousand (2012 - $4 thousand) for options granted to the Chief Financial Officer under the 2006 Stock Option Plan and $8 thousand (2012 - $20 thousand) for options granted to non-employee directors.		Included in management salaries are $6 thousand (2011 - $4 thousand) for options granted to the Chief Financial Officer and $6 thousand (2011 - $4 thousand) for options granted to the Chief Executive Officer under the 2006 Stock Option Plan and $23 thousand (2011 - $10 thousand) for options granted to non-employee directors.
		Also included in management salaries are director fees of $63 thousand (2012 - $80 thousand) for attendance to board meetings and audit committee meetings and $66 thousand (2012 - $Nil) for fees paid to a director under a management consultancy agreement.		Included in general and administrative expenses are director fees of $114 thousand (2011 - $87 thousand) for attendance at board meetings and audit committee meetings.
		The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed to by the related parties.		A short term loan of $85 thousand bearing interest at 1% per annum was provided to an employee, who is also an officer of the Company, on November 9, 2011. The loan amount, together with interest accrued, was repaid to the Company on February 28, 2012.
				In the year ended December 31, 2012 the amount included in accounts payable and accrued liabilities payable to shareholders, who are also officers of the Company, is $Nil (2011 - $1 thousand).
				The above related party transactions have been measured at the exchange amount which is the amount of the consideration established and agreed upon by the related parties.

Basic_and_Diluted_Loss_Per_Com

Basic and Diluted Loss Per Common Share	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Basic and Diluted Loss Per Common Share [Text Block]	'		'
	9	Basic and Diluted Loss Per Common Share	14.	Basic and Diluted Loss Per Common Share
		Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants, share-based compensation and convertible notes have been excluded from the calculation of diluted loss per share since they are anti-dilutive.		Basic and diluted loss per common share is calculated based on the weighted average number of shares outstanding during the period. The warrants and stock options have been excluded from the calculation of diluted loss per share since they are anti-dilutive.

Comparative_Figures

Comparative Figures	9 Months Ended
	Sep. 30, 2013
Comparative Figures [Text Block]	'
	10	Comparative Figures
		Certain reclassifications of September 30, 2012 amounts have been made to facilitate comparison with the current period.

Subsequent_Events

Subsequent Events	12 Months Ended
	Dec. 31, 2012
Subsequent Events [Text Block]	'
	15.	Subsequent Events
		Subsequent top the year ended December 31, 2012, 362,500 warrants were exercised for 362,500 common shares having a par value of $0 thousand for cash consideration of approximately $172 thousand, resulting in an increase in additional paid-in capital of approximately $172 thousand.

Summary_of_Significant_Account

Summary of Significant Accounting Policies (Policies)	9 Months Ended		12 Months Ended
	Sep. 30, 2013		Dec. 31, 2012
Revenue Recognition [Policy Text Block]	'		'
				Revenue Recognition
				The Company recognizes revenue from research and development contracts as the contracted services are performed or when milestones are achieved, in accordance with the terms of the specific agreements and when collection of the payment is reasonably assured. In addition, the performance criteria for the achievement of milestones are met if substantive effort was required to achieve the milestone and the amount of the milestone payment appears reasonably commensurate with the effort expended. Amounts received in advance of the recognition criteria being met, if any, are included in deferred income.
				IntelGenx has license agreements that specify that certain royalties are earned by the Company on sales of licensed products in the licensed territories. Licensees usually report sales and royalty information in the 45 days after the end of the quarter in which the activity takes place and typically do not provide forward estimates or current-quarter information. Because the Company is not able to reasonably estimate the amount of royalties earned during the period in which these licensees actually ship products, royalty revenue is not recognized until the royalties are reported to the Company and the collection of these royalties is reasonably assured.
				In August 2010 the Company entered into a joint development and commercialization agreement with RedHill Biopharma (“RedHill”), an Israeli company, for an anti-migraine product based upon the Company’s VersaFilm™ technology. In accordance with the terms of the agreement, RedHill made up-front and milestone payments in the aggregate amount of $600 thousand, of which $100 thousand was received by the Company in 2012 upon production of pivotal batches. RedHill is required to make additional milestone payments of up to $700,000 as follows:
				$200 thousand upon the filing of an NDA and acceptance of the filing by the U.S. Food and Drug Administration; and
				$500 thousand upon receipt of U.S. Food and Drug Administration marketing approval for the product.
Product Sales [Policy Text Block]	'		'
				Product Sales:
				The Company launched Forfivo XL™ in the USA in October 2012 under a licensing partnership with Edgemont Pharmaceuticals LLP (“Edgemont”). Under the terms of the agreement with Edgemont, the commercial launch of Forfivo XL™ triggered launch-related milestone payments for IntelGenx of up to $4.0 million, of which $1 million was invoiced by the Company to Edgemont and recognized as revenue in the fourth quarter of 2012 and the cash received in February 2013. Additional milestones of up to a further $23.5 million are payable upon achieving certain sales and exclusivity targets and the Company expects to commence receiving royalties from sales of the product in the first quarter of 2013.
				Upon entering into the licensing agreement, Edgemont paid the Company an upfront fee of $1 million, which the Company recognized as deferred license revenue. The deferred license revenue will be amortized in income over the period where sales of Forfivo XL™ are expected to be exclusive. As a result of this policy, the Company has a deferred revenue balance of $923 thousand at December 31, 2012 that has not been recognized as revenue.
Use of Estimates [Policy Text Block]	'		'
				Use of Estimates
				The preparation of financial statements in conformity with US GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. The financial statements include estimates based on currently available information and management's judgment as to the outcome of future conditions and circumstances. Significant estimates in these financial statements include the useful lives and impairment of long-lived assets, stock-based compensation costs, the investment tax credits receivable, the determination of the fair value of warrants issued as part of fundraising activities, and the resulting impact on the allocation of the proceeds between the common shares and the warrants.
				Changes in the status of certain facts or circumstances could result in material changes to the estimates used in the preparation of the financial statements and actual results could differ from the estimates and assumptions.
Financial Instruments [Policy Text Block]	'		'
				Financial Instruments
				The Company estimates the fair value of its financial instruments based on current interest rates, market value and pricing of financial instruments with comparable terms. Unless otherwise indicated, the carrying value of these financial instruments approximates their fair value.
Cash and Cash Equivalents [Policy Text Block]	'		'
				Cash and Cash Equivalents
				Cash and cash equivalents is comprised of cash on hand and term deposits with original maturity dates of less than three months that are stated at cost, which approximates fair value.
Accounts Receivable [Policy Text Block]	'		'
				Accounts Receivable
				The Company accounts for trade receivables at original invoice amount less an estimate made for doubtful receivables based on a review of all outstanding amounts on a quarterly basis. Management determines the allowance for doubtful accounts by regularly evaluating individual customer receivables and considering a customer's financial condition, credit history and current economic conditions. The Company writes off trade receivables when they are deemed uncollectible. In the first quarter of 2011, the Company wrote-off a receivable in the amount of $53 thousand that was owed to the Company by Circ Pharma Limited, Ireland, which was deemed to be no longer collectible. The Company records recoveries of trade receivables previously written-off when they receive them. Management has determined that no allowance for doubtful accounts is necessary in order to adequately cover exposure to loss in its December 31, 2012 accounts receivable (2011 - $Nil). The accounts receivable balance of $1,282 thousand as at December 31, 2012 includes $1 million from Edgemont that was received by IntelGenx in February 2013.
Investment Tax Credits [Policy Text Block]	'		'
				Investment Tax Credits
				Investment tax credits relating to qualifying expenditures are recognized in the accounts at the time at which the related expenditures are incurred and there is reasonable assurance of their realization. Management has made estimates and assumptions in determining the expenditures eligible for investment tax credits claimed.
Leasehold Improvements and Equipment [Policy Text Block]	'		'
				Leasehold Improvements and Equipment
				Leasehold Improvements and equipment are recorded at cost. Provisions for depreciation are based on their estimated useful lives using the methods as follows:
				On the declining balance method -
				Laboratory and office equipment	20%
				Computer equipment	30%
				On the straight-line method -
				Leasehold improvements	over the lease term
				Manufacturing equipment	5 – 10 years
			Upon retirement or disposal, the cost of the asset disposed of and the related accumulated depreciation are removed from the accounts and any gain or loss is reflected in income. Expenditures for repair and maintenance are expensed as incurred.
Intangible Assets [Policy Text Block]	'		'
			Intangible Assets
			Payments made to third parties subsequent to regulatory approval are capitalized and amortized over the remaining useful life of the related product. Amounts capitalized for such payments are included in other intangibles, net of accumulated amortization.
Impairment of Long-lived Assets [Policy Text Block]	'		'
			Impairment of Long-lived Assets
			Long-lived assets held and used by the Company are reviewed for possible impairment whenever events or changes in circumstances indicate the carrying amount of an asset may not be recoverable. Recoverability of assets to be held and used is measured by a comparison of the carrying amount of the assets to the estimated undiscounted cash flows expected to be generated by the asset. If such assets are considered to be impaired, the impairment to be recognized is measured by the amount by which the carrying amount of the asset exceeds the fair value thereof.
Foreign Currency Translation [Policy Text Block]	'		'
				Foreign Currency Translation
				The Company's reporting currency is the U.S. dollar. The Canadian dollar is the functional currency of the Company's Canadian operations, which is translated to the United States dollar using the current rate method. Under this method, accounts are translated as follows:
			Assets and liabilities - at exchange rates in effect at the balance sheet date;
			Revenue and expenses - at average exchange rates prevailing during the year;
			Equity - at historical rates.
			Gains and losses arising from foreign currency translation are included in other comprehensive income.
Income Taxes [Policy Text Block]	'		'
			Income Taxes
			The Company accounts for income taxes in accordance with FASB ASC 740 "Income Taxes". Deferred taxes are provided on the liability method whereby deferred tax assets are recognized for deductible temporary differences, and deferred tax liabilities are recognized for taxable temporary differences. Temporary differences are the differences between the reported amounts of assets and liabilities and their tax bases. Deferred tax assets are reduced by a valuation allowance when, in the opinion of management, it is more likely than not that some portion or all of the deferred tax assets will be realized. Deferred tax assets and liabilities are adjusted for the effects of changes in tax laws and rates on the date of enactment.
Unrecognized Tax Benefits [Policy Text Block]	'		'
			Unrecognized Tax Benefits
			The Company accounts for unrecognized tax benefits in accordance with FASB ASC 740 “Income Taxes”. ASC 740 prescribes a recognition threshold that a tax position is required to meet before being recognized in the financial statements and provides guidance on de-recognition, measurement, classification, interest and penalties, accounting in interim periods, disclosure and transition issues. ASC 740 contains a two-step approach to recognizing and measuring uncertain tax positions. The first step is to evaluate the tax position for recognition by determining if the weight of available evidence indicates that it is more likely than not that the position will be sustained upon ultimate settlement with a taxing authority, including resolution of related appeals or litigation processes, if any. The second step is to measure the tax benefit as the largest amount that is more than 50% likely of being realized upon ultimate settlement.
			Additionally, ASC 740 requires the Company to accrue interest and related penalties, if applicable, on all tax positions for which reserves have been established consistent with jurisdictional tax laws. The Company elected to classify interest and penalties related to the unrecognized tax benefits in the income tax provision.
Share-Based Payments [Policy Text Block]	'		'
				Share-Based Payments
				The Company accounts for share-based payments to employees in accordance with the provisions of FASB ASC 718 "Compensation—Stock Compensation" and accordingly recognizes in its financial statements share-based payments at their fair value. In addition, the Company will recognize in the financial statements an expense based on the grant date fair value of stock options granted to employees. The expense will be recognized on a straight-line basis over the vesting period and the offsetting credit will be recorded in additional paid-in capital. Upon exercise of options, the consideration paid together with the amount previously recorded as additional paid-in capital will be recognized as capital stock. The Company estimates its forfeiture rate in order to determine its compensation expense arising from stock-based awards. The Company uses the Black-Scholes option pricing model to determine the fair value of the options.
				The Company measures compensation expense for its non-employee stock-based compensation under ASC 505-50, “Accounting for Equity Instruments that are Issued to Other Than Employees for Acquiring, or in Conjunction with Selling, Goods or Services". The fair value of the option issued is used to measure the transaction, as this is more reliable than the fair value of the services received. The fair value is measured at the value of the Company’s common stock on the date that the commitment for performance by the counterparty has been reached or the counterparty’s performance is complete. The fair value of the equity instrument is charged directly to compensation expense and additional paid-in capital. For common stock issuances to non-employees that are fully vested and are for future periods, the Company classifies these issuances as prepaid expenses and expenses the prepaid expenses over the service period. At no time has the Company issued common stock for a period that exceeds one year.
Loss Per Share [Policy Text Block]	'		'
				Loss Per Share
				Basic loss per share is calculated based on the weighted average number of shares outstanding during the year. Any antidilutive instruments are excluded from the calculation of diluted loss per share.
Fair Value Measurements [Policy Text Block]	'		'
				Fair Value Measurements
				ASC 820 applies to all assets and liabilities that are being measured and reported on a fair value basis. ASC 820 requires new disclosure that establishes a framework for measuring fair value in US GAAP, and expands disclosure about fair value measurements. This statement enables the reader of the financial statements to assess the inputs used to develop those measurements by establishing a hierarchy for ranking the quality and reliability of the information used to determine fair values. The statement requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:
				Level 1:	Quoted market prices in active markets for identical assets or liabilities.
				Level 2:	Observable market based inputs or unobservable inputs that are corroborated by market data.
				Level 3:	Unobservable inputs that are not corroborated by market data.
			In determining the appropriate levels, the Company performs a detailed analysis of the assets and liabilities that are subject to ASC 820. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs are classified as Level 3. There are no assets or liabilities measured at fair value as at December 31, 2012.
Fair Value of Financial Instruments [Policy Text Block]	'		'
			Fair Value of Financial Instruments
			The fair value represents management’s best estimates based on a range of methodologies and assumptions. The carrying value of receivables and payables arising in the ordinary course of business and the investment tax credits receivable approximate fair value because of the relatively short period of time between their origination and expected realization.
Recent Accounting Pronouncements [Policy Text Block]	'		'
		Recently Issued Accounting Pronouncements
			Recent Accounting Pronouncements
		In February 2013, the FASB issued Update No. 2013-04, “Liabilities (Topic 405)—Obligations Resulting from Joint and Several Liability Arrangements for Which the Total Amount of the Obligation Is Fixed at the Reporting Date”. The amendments in this Update provide guidance for the recognition, measurement, and disclosure of obligations resulting from joint and several liability arrangements for which the total amount of the obligation within the scope of this Update is fixed at the reporting date, except for obligations addressed within existing guidance in U.S. GAAP. The guidance requires an entity to measure those obligations as the sum of the amount the reporting entity agreed to pay on the basis of its arrangement among its co-obligors and any additional amount the reporting entity expects to pay on behalf of its co-obligors. The guidance in this Update also requires an entity to disclose the nature and amount of the obligation as well as other information about those obligations. For public entities, the amendments in this ASU are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013. The amendments shall be applied retrospectively to all prior periods presented for those obligations that exist at the beginning of the fiscal year of adoption. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.
			In December 2011, the FASB issued Update No. 2011-11, “Balance Sheet (Topic 210): Disclosures about Offsetting Assets and Liabilities”. The objective of this Update is to provide enhanced disclosures that will enable users of its financial statements to evaluate the effect or potential effect of netting arrangements on an entity’s financial position. This includes the effect or potential effect of rights of setoff associated with an entity’s recognized assets and recognized liabilities within the scope of this Update. The amendments require enhanced disclosures by requiring improved information about financial instruments and derivative instruments that are either (1) offset in accordance with either Section 210-20-45 or Section 815-10-45 or (2) subject to an enforceable master netting arrangement or similar agreement, irrespective of whether they are offset in accordance with either Section 210-20-45 or Section 815-10-45. ASU 2011-11 is effective for annual reporting periods beginning on or after January 1, 2013, and interim periods within those annual periods. Retrospective disclosure is required for all comparative periods presented. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.
				In December 2011, the FASB issued Update No. 2011-12, “Comprehensive Income (Topic 220): Deferral of the Effective Date for Amendments to the Presentation of Reclassifications of Items Out of Accumulated Other Comprehensive Income in Accounting Standards Update No. 2011-05”. The amendments in this Update supersede changes to those paragraphs in Update 2011-05 that pertain to how, when, and where reclassification adjustments are presented. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations, but will affect the presentation of Other Comprehensive Income in the Company’s financial statements.
		In March 2013, the FASB issued Update No. 2013-05, “Foreign Currency Matters (Topic 830)—Parent’s Accounting for the Cumulative Translation Adjustment upon Derecognition of Certain Subsidiaries or Groups of Assets within a Foreign Entity or of an Investment in a Foreign Entity”. The amendments in this Update resolve the diversity in practice about whether Subtopic 810 - 10, Consolidation—Overall, or Subtopic 830-30, Foreign Currency Matters—Translation of Financial Statements, applies to the release of the cumulative translation adjustment into net income when a parent either sells a part or all of its investment in a foreign entity or no longer holds a controlling financial interest in a subsidiary or group of assets that is a nonprofit activity or a business (other than a sale of in substance real estate or conveyance of oil and gas mineral rights) within a foreign entity. In addition, the amendments in this Update resolve the diversity in practice for the treatment of business combinations achieved in stages (sometimes also referred to as step acquisitions) involving a foreign entity. For public entities, the amendments in this ASU are effective prospectively for fiscal years, and interim reporting periods within those years, beginning after December 15, 2013. Early adoption is permitted. The Company is currently evaluating the impact of this Statement on its consolidated financial statements.
		In April 2013, the FASB issued Update No. 2013-07, “Presentation of Financial Statements – Liquidation Basis of Accounting”. The objective of this Update is to clarify when an entity should apply the liquidation basis of accounting and to provide principles for the measurement of assets and liabilities under the liquidation basis of accounting, as well as any required disclosures. These amendments are effective for entities that determine liquidation is imminent during annual reporting periods beginning after December 15, 2013, and interim reporting periods therein. Entities should apply the requirements prospectively from the day that liquidation becomes imminent. Early adoption is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.
		In July 2013, the FASB issued Update No. 2013-11, “Income Taxes (Topic 740)—Presentation of an Unrecognized Tax Benefit When a Net Operating Loss Carryforward, a Similar Tax Loss, or a Tax Credit Carryforward Exists”. The amendments in this ASU provide guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward, similar tax loss, or tax credit carryforward exists. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2013 and should be applied prospectively to all unrecognized tax benefits that exist at the effective date. Early adoption and retrospective application is permitted. The adoption of this amendment is not expected to have a material effect on the Company’s financial position or results of operations.

Significant_Accounting_Policie1

Significant Accounting Policies (Tables)	21 Months Ended
	Sep. 30, 2013
Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment [Table Text Block]	'
		On the declining balance method -
		Laboratory and office equipment	20%
		Computer equipment	30%
		On the straight-line method -
		Leasehold improvements	over the lease term
		Manufacturing equipment	5 – 10 years

Leasehold_Improvements_and_Equ1

Leasehold Improvements and Equipment (Tables)	12 Months Ended
	Dec. 31, 2012
Schedule of Leasehold Improvements and Equipment [Table Text Block]	'
								2012		2011
		In US$ thousands				Accumulated		Net Carrying		Net Carrying
				Cost		Depreciation		Amount		Amount
		Manufacturing equipment	$	225	$	0	$	225	$	0
		Laboratory and office equipment		418		265		153		138
		Computer equipment		43		34		9		11
		Leasehold improvements		63		63		0		0
			$	749	$	362	$	387	$	149

Commitments_Tables

Commitments (Tables)	12 Months Ended
	Dec. 31, 2012
Schedule of future minimum payments under operating leases [Table Text Block]	'
	2013		15
	2014		0
	Total	$	15

Capital_Stock_Tables

Capital Stock (Tables)

9 Months Ended

12 Months Ended

Sep. 30, 2013

Dec. 31, 2012

Schedule of Stock by Class [Table Text Block]

'

'

September 30,

December 31,

2012

2011

2013

2012

Authorized -

Authorized -

100,000,000 common shares of $0.00001 par value

100,000,000 common shares of $0.00001 par value

20,000,000 preferred shares of $0.00001 par value

20,000,000 preferred shares of $0.00001 par value

Issued -

Issued -

49,890,421 (December 31, 2011 - 48,895,028) common shares

$

499

$

489

53,063,921 (December 31, 2012 - 49,890,421) common shares

$

531

$

499

Additional_PaidIn_Capital_Tabl

Additional Paid-In Capital (Tables)	9 Months Ended			12 Months Ended
	Sep. 30, 2013			Dec. 31, 2012
Schedule of Stock Options Valuation - May 12, 2011 [Table Text Block]	'			'
					Expected volatility	115%
					Expected life	3.1 years
					Risk-free interest rate	0.96%
					Dividend yield	nil
Schedule of Stock Options Valuation - November 29, 2011 [Table Text Block]	'			'
					Expected volatility	101%
					Expected life	3.1 years
					Risk-free interest rate	0.40%
					Dividend yield	nil
Schedule of Stock Options Valuation - June 13, 2012 [Table Text Block]	'			'
					Expected volatility	83%
					Expected life	3.1 years
					Risk-free interest rate	0.40%
					Dividend yield	nil
Schedule of Stock Options Valuation - August 8, 2012 [Table Text Block]	'			'
					Expected volatility	81%
					Expected life	1.8 years
					Risk-free interest rate	0.38%
					Dividend yield	nil
Schedule of Stock Options Valuation - December 4, 2012 [Table Text Block]	'			'
					Expected volatility	78%
					Expected life	3.1 years
					Risk-free interest rate	0.34%
					Dividend yield	nil
Schedule of Stock Options Valuation - December 12, 2012 [Table Text Block]	'			'
					Expected volatility	70%
					Expected life	1.8 years
					Risk-free interest rate	0.25%
					Dividend yield	nil
Schedule of Stock Option Activity [Table Text Block]	'			'
										Weighted average
							Number of options			exercise price
										$
					Outstanding – January 1, 2011		1,698,088			0.53
					Granted		290,000			0.54
					Forfeited		(150,000	)		(0.76	)
					Expired		(65,000	)		(0.59	)
					Exercised		(775,000	)		(0.41	)
					Outstanding – December 31, 2011		998,088			0.59
					Granted		195,000			0.57
					Forfeited		(45,000	)		(0.49	)
					Expired		(32,500	)		(1.15	)
					Exercised		(50,000	)		(0.55	)
					Outstanding – December 31, 2012		1,065,588			0.58
Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity [Table Text Block]	'			'
						Outstanding options								Exercisable options
												Weighted			Weighted
									Weighted average			average	Aggregate		average	Aggregate
				Exercise		Number of			remaining			exercise	intrinsic	Number of	exercise	intrinsic
				prices		options			contractual life			price	value	options	price	value
				$					(years)			$	$		$	$
				0.31		25,000			1.25			0.31		25,000	0.31
				0.37		75,000			2.67			0.37		75,000	0.37
				0.45-0.47		175,000			1.42			0.46		175,000	0.46
				0.51		40,000			4.5			0.51		0	0
				0.52-0.54		270,000			3.89			0.54		147,500	0.54
				0.55		50,000			2.67			0.55		12,500	0.55
				0.6		55,000			5			0.6		0	0
				0.61		125,000			1.51			0.61		125,000	0.61
				0.62		50,000			3			0.62		0	0
				0.85		200,588			0.63			0.85		200,588	0.85
						1,065,588			2.6			0.58	114,050	760,588	0.59	86,725
Schedule of Warrants Valuation - June 21, 2011 [Table Text Block]	'			'
					Expected volatility	117%
					Expected life	3 years
					Risk-free interest rate	0.69%
					Dividend yield	nil
Schedule of Warrants Valuation - June 21, 2011 [Table Text Block]	'			'
					Expected volatility	117%
					Expected life	3 years
					Risk-free interest rate	0.69%
					Dividend yield	nil
Schedule of Stockholders' Equity Note, Warrants or Rights, Activity [Table Text Block]	'			'
							Number of			Weighted average
							warrants			exercise price
							(All Exercisable)			$
					Outstanding – January 1, 2011		21,291,223			0.66
					Attached to private placements		2,748,165			0.74
					Agents’ warrants exercised		(299,406	)		(0.47	)
					Exercised		(4,366,904	)		(0.51	)
					Outstanding - December 31, 2011		19,373,078			0.71
					Agents’ warrants exercised		(219,313	)		(0.47	)
					Exercised		(1,205,668	)		(0.48	)
					Expired		(11,843,932	)		(0.80	)
					Outstanding - December 31, 2012		6,104,165			0.59
Schedule of 480,000 Stock Options Valuation - April 24, 2013 [Table Text Block]	'			'
		Expected volatility	78%
		Expected life	3.83 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
Schedule of 200,000 Stock Options Valuation - April 24, 2013 [Table Text Block]	'			'
		Expected volatility	77%
		Expected life	3.13 years
		Risk-free interest rate	0.34%
		Dividend yield	nil
Schedule of 35,000 Stock Options Valuation - August 6, 2013 [Table Text Block]	'			'
		Expected volatility	75%
		Expected life	3.13 years
		Risk-free interest rate	0.62%
		Dividend yield	nil

Income_Tax_Tables

Income Tax (Tables)	12 Months Ended
	Dec. 31, 2012
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	'
				2012			2011
		Statutory income taxes	$	( 605	)	$	( 694	)
		Net operating losses for which no tax benefits have been recorded		368			514
		Excess of depreciation over capital cost allowance		3			(2	)
		Non-deductible expenses		18			4
		Undeducted research and development expenses		273			231
		Tax deductible portion of transaction costs		-			-
		Investment tax credit		(57	)		(53	)
		Modification of warrants terms		-			-
			$	-		$	-
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	'
				2012			2011
		Leasehold Improvements and equipment	$	13		$	14
		Net operating losses carryforward		2,278			2,140
		Undeducted research and development expenses		1,301			1,141
		Non-refundable tax credits carryforward		914			807
				4,506			4,102
		Valuation allowance		(4,506	)		(4,102	)
			$	-		$	-

Statement_of_Cash_Flows_Inform1

Statement of Cash Flows Information (Tables)	12 Months Ended
	Dec. 31, 2012
Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]	'
		In US$ thousands		2012		2011
		Additional Cash Flow Information:
		Interest paid	$	3	$	3

Nature_of_Business_Narrative_D

Nature of Business (Narrative) (Details)	12 Months Ended
	Dec. 31, 2012
Nature Of Business 1	9
Nature Of Business 2	6
Nature Of Business 3	2

Significant_Accounting_Policie2

Significant Accounting Policies (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	D
Significant Accounting Policies 1	45
Significant Accounting Policies 2	$600,000
Significant Accounting Policies 3	100,000
Significant Accounting Policies 4	700,000
Significant Accounting Policies 5	200,000
Significant Accounting Policies 6	500,000
Significant Accounting Policies 7	4,000,000
Significant Accounting Policies 8	1,000,000
Significant Accounting Policies 9	23,500,000
Significant Accounting Policies 10	1,000,000
Significant Accounting Policies 11	923,000
Significant Accounting Policies 12	53,000
Significant Accounting Policies 13	0
Significant Accounting Policies 14	1,282,000
Significant Accounting Policies 15	$1,000,000
Significant Accounting Policies 16	50.00%

Intangible_Assets_Narrative_De

Intangible Assets (Narrative) (Details) (USD $)	9 Months Ended	12 Months Ended
In Thousands, unless otherwise specified	Sep. 30, 2013	Dec. 31, 2012
	M	M
Intangible Assets 1	$87	'
Intangible Assets 2	116	'
Intangible Assets 3	100.00%	'
Intangible Assets 4	39	'
Intangible Assets 1	'	116
Intangible Assets 2	'	$125
Intangible Assets 3	'	100.00%
Intangible Assets 4	'	39

Deferred_License_Revenue_Narra

Deferred License Revenue (Narrative) (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
	M	M
Deferred License Revenue 1	$1,000,000	'
Deferred License Revenue 2	39	'
Deferred License Revenue 3	694,000	'
Deferred License Revenue 1	'	1,000,000
Deferred License Revenue 2	'	39
Deferred License Revenue 3	'	$923,000

Commitments_Narrative_Details

Commitments (Narrative) (Details)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012	Dec. 31, 2012
	USD ($)	CAD
	Y
Commitments 1	3,500	3,500
Commitments 2	6,425	6,425
Commitments 3	28,600	28,600
Commitments 4	10	10
Commitments 5	$4	'
Commitments 6	'	5
Commitments 7	5	'
Commitments 8	2	'
Commitments 9	'	2
Commitments 10	$2	'
Commitments 11	10.00%	10.00%

Capital_Stock_Narrative_Detail

Capital Stock (Narrative) (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	M
Capital Stock 1	4,800,000
Capital Stock 2	2,400,000
Capital Stock 3	$3,200,000
Capital Stock 4	0.74
Capital Stock 5	36
Capital Stock 6	2,024,000
Capital Stock 7	2,582,536
Capital Stock 8	1,291,268
Capital Stock 9	1,700,000
Capital Stock 10	2,238,806
Capital Stock 11	1,119,403
Capital Stock 12	1,500,000
Capital Stock 13	121,000
Capital Stock 14	7.00%
Capital Stock 15	28,000
Capital Stock 16	180,778
Capital Stock 17	7.00%
Capital Stock 18	105,000
Capital Stock 19	7.00%
Capital Stock 20	156,716
Capital Stock 21	7.00%
Capital Stock 22	0.74
Capital Stock 23	36
Capital Stock 24	114,000
Capital Stock 25	50,000
Capital Stock 26	775,000
Capital Stock 27	50,000
Capital Stock 28	775,000
Capital Stock 29	0
Capital Stock 30	0
Capital Stock 31	28,000
Capital Stock 32	318,000
Capital Stock 33	28,000
Capital Stock 34	318,000
Capital Stock 35	219,313
Capital Stock 36	299,406
Capital Stock 37	219,313
Capital Stock 38	299,406
Capital Stock 39	0
Capital Stock 40	104,000
Capital Stock 41	142,000
Capital Stock 42	104,000
Capital Stock 43	142,000
Capital Stock 44	1,205,668
Capital Stock 45	491,382
Capital Stock 46	491,382
Capital Stock 47	0
Capital Stock 48	233,000
Capital Stock 49	233,000
Capital Stock 50	714,286
Capital Stock 51	234,698
Capital Stock 52	0
Capital Stock 53	4,366,904
Capital Stock 54	2,902,618
Capital Stock 55	2,902,618
Capital Stock 56	0
Capital Stock 57	1,458,000
Capital Stock 58	1,458,000
Capital Stock 59	1,464,286
Capital Stock 60	515,391
Capital Stock 61	$0

Additional_PaidIn_Capital_Narr

Additional Paid-In Capital (Narrative) (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
	Y	Y
		M
Additional Paid-in Capital 1	480,000	'
Additional Paid-in Capital 2	$0.65	'
Additional Paid-in Capital 3	$157,000	'
Additional Paid-in Capital 4	200,000	'
Additional Paid-in Capital 5	$0.65	'
Additional Paid-in Capital 6	2	'
Additional Paid-in Capital 7	25.00%	'
Additional Paid-in Capital 8	59,000	'
Additional Paid-in Capital 9	35,000	'
Additional Paid-in Capital 10	$0.65	'
Additional Paid-in Capital 11	2	'
Additional Paid-in Capital 12	25.00%	'
Additional Paid-in Capital 13	10,000	'
Additional Paid-in Capital 18	75,000	'
Additional Paid-in Capital 19	0	'
Additional Paid-in Capital 20	75,000	'
Additional Paid-in Capital 21	0	'
Additional Paid-in Capital 22	0	'
Additional Paid-in Capital 23	31,000	'
Additional Paid-in Capital 24	0	'
Additional Paid-in Capital 25	31,000	'
Additional Paid-in Capital 26	0	'
Additional Paid-in Capital 27	82,000	'
Additional Paid-in Capital 28	43,000	'
Additional Paid-in Capital 29	67,000	'
Additional Paid-in Capital 30	41,000	'
Additional Paid-in Capital 31	15,000	'
Additional Paid-in Capital 32	1,000	'
Additional Paid-in Capital 33	1,000	'
Additional Paid-in Capital 34	202,000	'
Additional Paid-in Capital 35	63,000	'
Additional Paid-in Capital 36	3,098,500	'
Additional Paid-in Capital 37	1,424,981	'
Additional Paid-in Capital 38	3,098,500	'
Additional Paid-in Capital 39	945,393	'
Additional Paid-in Capital 40	0	'
Additional Paid-in Capital 41	1,465,000	'
Additional Paid-in Capital 42	337,000	'
Additional Paid-in Capital 43	1,464,000	'
Additional Paid-in Capital 44	337,000	'
Additional Paid-in Capital 1	'	1,600,749
Additional Paid-in Capital 2	'	100.00%
Additional Paid-in Capital 3	'	10
Additional Paid-in Capital 4	'	24
Additional Paid-in Capital 5	'	100.00%
Additional Paid-in Capital 6	'	1,600,749
Additional Paid-in Capital 7	'	2,074,000
Additional Paid-in Capital 8	'	10.00%
Additional Paid-in Capital 9	'	10
Additional Paid-in Capital 10	'	5
Additional Paid-in Capital 11	'	2,074,000
Additional Paid-in Capital 12	'	3,308,127
Additional Paid-in Capital 13	'	10.00%
Additional Paid-in Capital 14	'	50,000
Additional Paid-in Capital 15	'	$0.52
Additional Paid-in Capital 16	'	2
Additional Paid-in Capital 17	'	25.00%
Additional Paid-in Capital 18	'	16,000
Additional Paid-in Capital 19	'	115,000
Additional Paid-in Capital 20	'	40,000
Additional Paid-in Capital 21	'	50,000
Additional Paid-in Capital 22	'	35,000
Additional Paid-in Capital 23	'	$0.54
Additional Paid-in Capital 24	'	2
Additional Paid-in Capital 25	'	25.00%
Additional Paid-in Capital 26	'	74,000
Additional Paid-in Capital 27	'	40,000
Additional Paid-in Capital 28	'	$0.51
Additional Paid-in Capital 29	'	2
Additional Paid-in Capital 30	'	25.00%
Additional Paid-in Capital 31	'	10,000
Additional Paid-in Capital 32	'	50,000
Additional Paid-in Capital 33	'	$0.55
Additional Paid-in Capital 34	'	1
Additional Paid-in Capital 35	'	25.00%
Additional Paid-in Capital 36	'	12,000
Additional Paid-in Capital 37	'	30,000
Additional Paid-in Capital 38	'	25,000
Additional Paid-in Capital 39	'	$0.60
Additional Paid-in Capital 40	'	2
Additional Paid-in Capital 41	'	25.00%
Additional Paid-in Capital 42	'	15,000
Additional Paid-in Capital 43	'	50,000
Additional Paid-in Capital 44	'	$0.62
Additional Paid-in Capital 45	'	1
Additional Paid-in Capital 46	'	25.00%
Additional Paid-in Capital 47	'	10,000
Additional Paid-in Capital 48	'	50,000
Additional Paid-in Capital 49	'	775,000
Additional Paid-in Capital 50	'	50,000
Additional Paid-in Capital 51	'	775,000
Additional Paid-in Capital 52	'	0
Additional Paid-in Capital 53	'	0
Additional Paid-in Capital 54	'	28,000
Additional Paid-in Capital 55	'	318,000
Additional Paid-in Capital 56	'	28,000
Additional Paid-in Capital 57	'	318,000
Additional Paid-in Capital 58	'	4,000
Additional Paid-in Capital 59	'	59,000
Additional Paid-in Capital 60	'	51,000
Additional Paid-in Capital 61	'	72,000
Additional Paid-in Capital 62	'	92,000
Additional Paid-in Capital 63	'	17,000
Additional Paid-in Capital 64	'	0
Additional Paid-in Capital 65	'	72,000
Additional Paid-in Capital 66	'	55,000
Additional Paid-in Capital 67	'	4,800,000
Additional Paid-in Capital 68	'	2,400,000
Additional Paid-in Capital 69	'	$0.74
Additional Paid-in Capital 70	'	817,000
Additional Paid-in Capital 71	'	300,000
Additional Paid-in Capital 72	'	300,000
Additional Paid-in Capital 73	'	$0.74
Additional Paid-in Capital 74	'	153,000
Additional Paid-in Capital 75	'	219,313
Additional Paid-in Capital 76	'	299,406
Additional Paid-in Capital 77	'	219,313
Additional Paid-in Capital 78	'	299,406
Additional Paid-in Capital 79	'	0
Additional Paid-in Capital 80	'	104,000
Additional Paid-in Capital 81	'	142,000
Additional Paid-in Capital 82	'	104,000
Additional Paid-in Capital 83	'	142,000
Additional Paid-in Capital 84	'	1,205,668
Additional Paid-in Capital 85	'	491,382
Additional Paid-in Capital 86	'	491,382
Additional Paid-in Capital 87	'	0
Additional Paid-in Capital 88	'	233,000
Additional Paid-in Capital 89	'	233,000
Additional Paid-in Capital 90	'	714,286
Additional Paid-in Capital 91	'	234,698
Additional Paid-in Capital 92	'	0
Additional Paid-in Capital 93	'	4,366,904
Additional Paid-in Capital 94	'	2,902,618
Additional Paid-in Capital 95	'	2,902,618
Additional Paid-in Capital 96	'	0
Additional Paid-in Capital 97	'	1,458,000
Additional Paid-in Capital 98	'	1,458,000
Additional Paid-in Capital 99	'	1,464,286
Additional Paid-in Capital 100	'	515,391
Additional Paid-in Capital 101	'	$0

Income_Tax_Narrative_Details

Income Tax (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, unless otherwise specified	Dec. 31, 2012
Income Tax 1	$4,102
Income Tax 2	404
Income Tax 3	8,390
Income Tax 4	7,608
Income Tax 5	8,566
Income Tax 6	7,437
Income Tax 7	914
Income Tax 8	803
Income Tax 9	24
Income Tax 10	213
Income Tax 11	193
Income Tax 12	186
Income Tax 13	187
Income Tax 14	111
Income Tax 15	4,464
Income Tax 16	$3,656

Related_Party_Transactions_Nar

Related Party Transactions (Narrative) (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Related Party Transactions 1	$8,000	'
Related Party Transactions 2	5,000	'
Related Party Transactions 3	24,000	'
Related Party Transactions 4	0	'
Related Party Transactions 5	19,000	'
Related Party Transactions 6	4,000	'
Related Party Transactions 7	8,000	'
Related Party Transactions 8	20,000	'
Related Party Transactions 9	63,000	'
Related Party Transactions 10	80,000	'
Related Party Transactions 11	66,000	'
Related Party Transactions 12	0	'
Related Party Transactions 1	'	6,000
Related Party Transactions 2	'	4,000
Related Party Transactions 3	'	6,000
Related Party Transactions 4	'	4,000
Related Party Transactions 5	'	23,000
Related Party Transactions 6	'	10,000
Related Party Transactions 7	'	114,000
Related Party Transactions 8	'	87,000
Related Party Transactions 9	'	85,000
Related Party Transactions 10	'	1.00%
Related Party Transactions 11	'	0
Related Party Transactions 12	'	$1,000

Subsequent_Events_Narrative_De

Subsequent Events (Narrative) (Details) (USD $)	12 Months Ended
In Thousands, except Share data, unless otherwise specified	Dec. 31, 2012
Subsequent Events 1	362,500
Subsequent Events 2	362,500
Subsequent Events 3	$0
Subsequent Events 4	172
Subsequent Events 5	$172

Schedule_of_Estimated_Useful_L

Schedule of Estimated Useful Lives of Leasehold Improvements and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Significant Accounting Policies Schedule Of Estimated Useful Lives Of Leashold Improvements And Equipment 1	20.00%
Significant Accounting Policies Schedule Of Estimated Useful Lives Of Leashold Improvements And Equipment 2	30.00%
Significant Accounting Policies Schedule Of Estimated Useful Lives Of Leashold Improvements And Equipment 3	$5
Significant Accounting Policies Schedule Of Estimated Useful Lives Of Leashold Improvements And Equipment 4	10

Schedule_of_Leasehold_Improvem

Schedule of Leasehold Improvements and Equipment (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 1	$225
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 2	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 3	225
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 4	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 5	418
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 6	265
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 7	153
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 8	138
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 9	43
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 10	34
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 11	9
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 12	11
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 13	63
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 14	63
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 15	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 16	0
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 17	749
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 18	362
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 19	387
Leasehold Improvements And Equipment Schedule Of Leasehold Improvements And Equipment 20	$149

Schedule_of_future_minimum_pay

Schedule of future minimum payments under operating leases (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Commitments Schedule Of Future Minimum Payments Under Operating Leases 1	$15
Commitments Schedule Of Future Minimum Payments Under Operating Leases 2	0
Commitments Schedule Of Future Minimum Payments Under Operating Leases 3	$15

Schedule_of_Stock_by_Class_Det

Schedule of Stock by Class (Details) (USD $)	9 Months Ended	12 Months Ended
	Sep. 30, 2013	Dec. 31, 2012
Capital Stock Schedule Of Stock By Class 1	100,000,000	'
Capital Stock Schedule Of Stock By Class 2	$0.00	'
Capital Stock Schedule Of Stock By Class 3	20,000,000	'
Capital Stock Schedule Of Stock By Class 4	0.00001	'
Capital Stock Schedule Of Stock By Class 5	53,063,921	'
Capital Stock Schedule Of Stock By Class 6	49,890,421	'
Capital Stock Schedule Of Stock By Class 7	531	'
Capital Stock Schedule Of Stock By Class 8	499	'
Capital Stock Schedule Of Stock By Class 1	'	0
Capital Stock Schedule Of Stock By Class 2	'	100,000,000
Capital Stock Schedule Of Stock By Class 3	'	0.00001
Capital Stock Schedule Of Stock By Class 4	'	20,000,000
Capital Stock Schedule Of Stock By Class 5	'	0.00001
Capital Stock Schedule Of Stock By Class 6	'	0
Capital Stock Schedule Of Stock By Class 7	'	49,890,421
Capital Stock Schedule Of Stock By Class 8	'	48,895,028
Capital Stock Schedule Of Stock By Class 9	'	499
Capital Stock Schedule Of Stock By Class 10	'	$489

Schedule_of_Stock_Options_Valu

Schedule of Stock Options Valuation - May 12, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 1	115.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 3	0.96%
Additional Paid-in Capital Schedule Of Stock Options Valuation - May 12, 2011 4	$0

Schedule_of_Stock_Options_Valu1

Schedule of Stock Options Valuation - November 29, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 1	101.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 3	0.40%
Additional Paid-in Capital Schedule Of Stock Options Valuation - November 29, 2011 4	$0

Schedule_of_Stock_Options_Valu2

Schedule of Stock Options Valuation - June 13, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 1	83.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 3	0.40%
Additional Paid-in Capital Schedule Of Stock Options Valuation - June 13, 2012 4	$0

Schedule_of_Stock_Options_Valu3

Schedule of Stock Options Valuation - August 8, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 1	81.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 2	1.8
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 3	0.38%
Additional Paid-in Capital Schedule Of Stock Options Valuation - August 8, 2012 4	$0

Schedule_of_Stock_Options_Valu4

Schedule of Stock Options Valuation - December 4, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 1	78.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 2	3.1
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 3	0.34%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 4, 2012 4	$0

Schedule_of_Stock_Options_Valu5

Schedule of Stock Options Valuation - December 12, 2012 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 1	70.00%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 2	1.8
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 3	0.25%
Additional Paid-in Capital Schedule Of Stock Options Valuation - December 12, 2012 4	$0

Schedule_of_Stock_Option_Activ

Schedule of Stock Option Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Additional Paid-in Capital Schedule Of Stock Option Activity 1	$1,698,088
Additional Paid-in Capital Schedule Of Stock Option Activity 2	0.53
Additional Paid-in Capital Schedule Of Stock Option Activity 3	290,000
Additional Paid-in Capital Schedule Of Stock Option Activity 4	0.54
Additional Paid-in Capital Schedule Of Stock Option Activity 5	-150,000
Additional Paid-in Capital Schedule Of Stock Option Activity 6	-0.76
Additional Paid-in Capital Schedule Of Stock Option Activity 7	-65,000
Additional Paid-in Capital Schedule Of Stock Option Activity 8	-0.59
Additional Paid-in Capital Schedule Of Stock Option Activity 9	-775,000
Additional Paid-in Capital Schedule Of Stock Option Activity 10	-0.41
Additional Paid-in Capital Schedule Of Stock Option Activity 11	998,088
Additional Paid-in Capital Schedule Of Stock Option Activity 12	0.59
Additional Paid-in Capital Schedule Of Stock Option Activity 13	195,000
Additional Paid-in Capital Schedule Of Stock Option Activity 14	0.57
Additional Paid-in Capital Schedule Of Stock Option Activity 15	-45,000
Additional Paid-in Capital Schedule Of Stock Option Activity 16	-0.49
Additional Paid-in Capital Schedule Of Stock Option Activity 17	-32,500
Additional Paid-in Capital Schedule Of Stock Option Activity 18	-1.15
Additional Paid-in Capital Schedule Of Stock Option Activity 19	-50,000
Additional Paid-in Capital Schedule Of Stock Option Activity 20	-0.55
Additional Paid-in Capital Schedule Of Stock Option Activity 21	$1,065,588
Additional Paid-in Capital Schedule Of Stock Option Activity 22	0.58

Schedule_of_Sharebased_Compens

Schedule of Share-based Compensation, Stock Options, and Warrants or Rights Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 1	0.31
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 2	$25,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 3	1.25
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 4	0.31
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 5	25,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 6	0.31
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 7	0.37
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 8	75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 9	2.67
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 10	0.37
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 11	75,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 12	0.37
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 13	175,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 14	1.42
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 15	0.46
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 16	175,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 17	0.46
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 18	0.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 19	40,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 20	4.5
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 21	0.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 22	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 23	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 24	270,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 25	3.89
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 26	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 27	147,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 28	0.54
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 29	0.55
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 30	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 31	2.67
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 32	0.55
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 33	12,500
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 34	0.55
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 35	0.6
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 36	55,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 37	5
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 38	0.6
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 39	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 40	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 41	0.61
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 42	125,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 43	1.51
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 44	0.61
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 45	125,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 46	0.61
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 47	0.62
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 48	50,000
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 49	3
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 50	0.62
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 51	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 52	0
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 53	0.85
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 54	200,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 55	0.63
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 56	0.85
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 57	200,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 58	0.85
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 59	1,065,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 60	2.6
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 61	0.58
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 62	114,050
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 63	760,588
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 64	0.59
Additional Paid-in Capital Schedule Of Share-based Compensation, Stock Options, And Warrants Or Rights Activity 65	$86,725

Schedule_of_Warrants_Valuation

Schedule of Warrants Valuation - June 21, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 1	117.00%
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 2	3
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 3	0.69%
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 4	$0

Schedule_of_Warrants_Valuation1

Schedule of Warrants Valuation - June 21, 2011 (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
	Y
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 1	117.00%
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 2	3
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 3	0.69%
Additional Paid-in Capital Schedule Of Warrant Valuation - June 21, 2011 4	$0

Schedule_of_Stockholders_Equit

Schedule of Stockholders' Equity Note, Warrants or Rights, Activity (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 1	$21,291,223
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 2	0.66
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 3	2,748,165
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 4	0.74
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 5	-299,406
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 6	-0.47
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 7	-4,366,904
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 8	-0.51
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 9	19,373,078
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 10	0.71
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 11	-219,313
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 12	-0.47
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 13	-1,205,668
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 14	-0.48
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 15	-11,843,932
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 16	-0.8
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 17	$6,104,165
Additional Paid-in Capital Schedule Of Stockholders' Equity Note, Warrants Or Rights, Activity 18	0.59

Schedule_of_480000_Stock_Optio

Schedule of 480,000 Stock Options Valuation - April 24, 2013 (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
	Y
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 1	78.00%
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 2	3.83
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 3	0.34%
Additional Paid-in Capital Schedule Of 480,000 Stock Options Valuation - April 24, 2013 4	$0

Schedule_of_200000_Stock_Optio

Schedule of 200,000 Stock Options Valuation - April 24, 2013 (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
	Y
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 1	77.00%
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 2	3.13
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 3	0.34%
Additional Paid-in Capital Schedule Of 200,000 Stock Options Valuation - April 24, 2013 4	$0

Schedule_of_35000_Stock_Option

Schedule of 35,000 Stock Options Valuation - August 6, 2013 (Details) (USD $)	9 Months Ended
	Sep. 30, 2013
	Y
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 1	75.00%
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 2	3.13
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 3	0.62%
Additional Paid-in Capital Schedule Of 35,000 Stock Options Valuation - August 6, 2013 4	$0

Schedule_of_Effective_Income_T

Schedule of Effective Income Tax Rate Reconciliation (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 1	$605
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 2	694
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 3	368
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 4	514
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 5	3
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 6	-2
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 7	18
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 8	4
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 9	273
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 10	231
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 11	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 12	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 13	-57
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 14	-53
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 15	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 16	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 17	0
Income Tax Schedule Of Effective Income Tax Rate Reconciliation 18	$0

Schedule_of_Deferred_Tax_Asset

Schedule of Deferred Tax Assets and Liabilities (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Income Tax Schedule Of Deferred Tax Assets And Liabilities 1	$13
Income Tax Schedule Of Deferred Tax Assets And Liabilities 2	14
Income Tax Schedule Of Deferred Tax Assets And Liabilities 3	2,278
Income Tax Schedule Of Deferred Tax Assets And Liabilities 4	2,140
Income Tax Schedule Of Deferred Tax Assets And Liabilities 5	1,301
Income Tax Schedule Of Deferred Tax Assets And Liabilities 6	1,141
Income Tax Schedule Of Deferred Tax Assets And Liabilities 7	914
Income Tax Schedule Of Deferred Tax Assets And Liabilities 8	807
Income Tax Schedule Of Deferred Tax Assets And Liabilities 9	4,506
Income Tax Schedule Of Deferred Tax Assets And Liabilities 10	4,102
Income Tax Schedule Of Deferred Tax Assets And Liabilities 11	-4,506
Income Tax Schedule Of Deferred Tax Assets And Liabilities 12	-4,102
Income Tax Schedule Of Deferred Tax Assets And Liabilities 13	0
Income Tax Schedule Of Deferred Tax Assets And Liabilities 14	$0

Schedule_of_Cash_Flow_Suppleme

Schedule of Cash Flow, Supplemental Disclosures (Details) (USD $)	12 Months Ended
	Dec. 31, 2012
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 1	$3
Statement Of Cash Flows Information Schedule Of Cash Flow, Supplemental Disclosures 2	$3